A study of two diuretic/potassium combinations in heart failure

Area of Science:

• Pharmacology
• Nephrology
• Internal Medicine

Background:

• Loop diuretics, such as frusemide and bumetanide, are commonly prescribed for fluid management.
• Long-term use of loop diuretics can lead to hypokalemia (low plasma potassium levels).
• Hypokalemia can cause significant adverse health effects, necessitating management strategies.

Purpose of the Study:

• To evaluate the efficacy of potassium supplements in patients receiving long-term frusemide therapy.
• To compare the effects of frusemide, bumetanide, and their potassium-combined formulations on plasma potassium levels.

Main Methods:

• A study involving 28 patients on long-term frusemide (40-80 mg daily) assessed plasma potassium changes with and without supplements.
• A crossover study in 14 patients compared frusemide, Diumide K (frusemide/potassium), bumetanide, and Burinex K (bumetanide/potassium).

Main Results:

• Plasma potassium levels decreased when frusemide therapy was initiated without supplements.
• Combined formulations (Diumide K, Burinex K) significantly increased plasma potassium but did not fully restore levels to baseline.
• Bumetanide resulted in higher plasma potassium than frusemide at equivalent doses.

Conclusions:

• Small doses of potassium in combined formulations are effective in mitigating mild hypokalemia caused by loop diuretics.
• Potassium supplementation is a viable strategy to manage diuretic-induced hypokalemia in patients on long-term therapy.